Neogen (NEOG) vs Intellia Therapeutics (NTLA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Neogen (NEOG) has outperformed Intellia Therapeutics (NTLA) over the past year, gaining 101.2% versus a loss of 48.5%. Over five years, NEOG leads with a -71.5% price change compared with -90.3% for NTLA. Neogen is the larger company by market cap ($2.59 billion vs $1.76 billion), about 1.5 times the size, while Intellia Therapeutics is growing revenue faster (+16.9% vs -2.7%).
Neogen converts more of its revenue into profit, with a net margin of -0.9% versus -609.9%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NEOG | NTLA |
|---|---|---|
| Share price | $11.86 | $12.55 |
| Market cap | $2.59B | $1.76B |
| 1-day change | +1.24% | -0.44% |
| YTD return | +67.53% | +40.16% |
| 1-year return | +101.20% | -48.51% |
| 5-year return | -71.47% | -90.34% |
| Forward P/E | 31.20 | — |
| EPS (TTM) | $-0.26 | $-3.35 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $870.40M | $67.67M |
| Revenue growth (YoY) | -2.72% | +16.92% |
| Net income (latest FY) | $-7.90M | $-412.69M |
| Gross margin | 46.93% | — |
| Operating margin | -2.48% | -651.67% |
| Net margin | -0.91% | -609.85% |
| 52-week high | $14.26 | $28.25 |
| 52-week low | $5.37 | $7.95 |
| Distance from 52-week high | -16.87% | -55.59% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +18.09% | +84.22% |
| Average volume | 3.14M | 4.26M |
| Shares outstanding | 218.31M | 140.13M |
| Employees | 2,636 | 377 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NEOG has outperformed NTLA by 149.7 percentage points over the past year.
- Neogen is more profitable, keeping -0.9 cents of every revenue dollar as net income versus -609.9 cents for Intellia Therapeutics.
- Intellia Therapeutics grew revenue faster in its latest fiscal year (+16.92% vs -2.72%).
About Neogen
NEOG stock →Neogen Corporation develops, manufactures, and markets various products and services for food and animal safety in the United States and internationally. It operates through Food Safety and Animal Safety segments.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 2,636 employees
About Intellia Therapeutics
NTLA stock →Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 377 employees
NEOG vs NTLA FAQ
Which is bigger, Neogen or Intellia Therapeutics?
Neogen (NEOG) is larger, with a market capitalization of $2.59B compared with $1.76B for Intellia Therapeutics (NTLA).
Which stock has performed better over the past year, NEOG or NTLA?
NEOG returned +101.20% over the past 12 months, compared with -48.51% for NTLA (price return, excluding dividends). Past performance does not predict future results.
Are Neogen and Intellia Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.